Introduction
A fter curative therapy for prostate cancer, a rising PSA may indicate persistent or recurrent disease. Conventional imaging techniques such as 111 Indium-capromabpendetide (ProstaScint), CT, US, and MRI have limitations for detecting recurrence [1, 2] . Differentiating recurrence to the prostate bed or to locoregional lymph nodes and distant sites is important in tailoring subsequent therapy, especially the use of salvage techniques [3] . Various [4, 5] . Amino acids are important nutrients for tumor growth. PETlabeled amino-acid-based tracers have been studied to image carcinoma [5, 6] . Aminocyclopentane carboxylic acid (ACPC) is an unnatural alicyclic amino acid, which was originally developed as a therapeutic agent for malignant tumors via competitive inhibition of valine synthesis by tumor cells. Anti-2-[ 18 F]FACPC is an ACPC analog with high uptake in the DU-145 prostate cancer cell line in vitro [7] [8] [9] .
We hypothesized anti- 
Materials and Methods

Preparation of anti-[
F]FACPC
The preparation of enantiomerically enriched (ee=90%) anti-2-[ 18 F] FACPC has been previously reported [8, 9] . The decay corrected radiochemical yield of the desired product was 25% (n=5), and its radiochemical purity was 99% at 80 min after end of bombardment. The injected mass was approximately 1.13 μg or 8.2 nmol per 10 mCi dose, and the specific activity was 1.2 Ci/μmol.
Patient Selection
All studies were performed under the auspices of the Emory University Institutional Review Board and the Food and Drug Administration (E-IND 105,456). Safety monitoring during the radiotracer infusion, as well as laboratory evaluation before and after the scan were carried out. Enrolled patients were eligible if they had undergone definitive local therapy for prostate carcinoma, and who met ASTRO or Phoenix criteria for biochemical failure with rising PSA without evidence of bone involvement on bone scan. Patients who had adjuvant hormonal therapy in the last 6 months were excluded. Five patients were randomly selected within the context of a clinical trial of the amino-acid analog, anti-[ 18 F]FACBC PET-CT, to provide intra-patient comparison of the two radiotracers [10, 11] .
PET Imaging Protocol
All scanning was conducted on a Discovery DLS integrated PET-CT scanner (GE, Milwaukee, WI), and the images were interpreted on a workstation utilizing 18 F]FACBC PET/CT scan was acquired in a manner previously reported [10, 11] . Ratio (n=6, n=7)
Lesion/Bladder SUV max /SUV mean Ratio (n=6, n=7)
Ratios are calculated using individual patient background data. See text for detailed explanation n individual data points, not patients
Image Analysis
All anti-2-[ 18 F]FACPC PET-CT images were interpreted by a nuclear radiologist with 14 years experience. Each lesion was visually assessed for activity and compared against the anti-[
18 F] FACBC PET-CT scan performed the day before. SUVmax of abnormal focal radiotracer uptake within prostate, lymph node, or bone were reported, as well as SUVmean of blood pool and bladder background activity on early (5 min) and delayed (20 min) images. These areas of focal uptake were compared with uptake in the separately acquired and blindly interpreted anti-[
18 F]FACBC studies at similar time points. Time activity curves were also recorded for lesions and background structures (bladder, femoral artery, iliac marrow, gluteus muscle) in individual patients. 
Correlation of Imaging to Clinical and Pathologic Data
Statistics
Descriptive statistics and independent samples T-test for evaluating differences between groups were performed using SPSS version 17.0 software (SPSS, Chicago, IL). P value less than 0.05 was considered significant.
Results
Five patients were included in this study. For the anti-[
18 F] FACBC PET-CT scan 1/5 patients had no uptake suspicious for recurrence, 2/5 patients had prostate bed and/or seminal vesicle recurrence, and 2/5 had prostate and/or lymph node uptake, confirmed to be recurrent prostate carcinoma by biopsy. Similar findings were noted for anti- with time confirming our visual impression that bladder activity is much more intense, obscuring the pelvic lesions. Figure 2 illustrates the different patterns in one of the study patients of lesion to background radiotracer activity in early and delayed images for anti-2-[
18 F]FACPC and anti-
A representative time-activity curve taken from a patient with a seminal vesicle lesion is plotted in Fig. 3a and shows maximum uptake of anti-[
18 F]FACPC at 7.5 min followed by a slow washout (1.0%/min) that matches blood pool. Regions in marrow (ilium) and muscle (gluteus) reached a plateau at 10 min and remained constant throughout the imaging period. Bladder uptake was about 20 times that of the lesion and peaked at 30 min. Another representative time-activity curve taken from a patient with a lesion in one obturator node is plotted in Fig. 3b and shows a time to peak uptake at 3 min followed by a faster washout (3.2%/min). Blood pool, muscle, marrow, and bladder time-activity data are consistent with that in Fig. 3a .
Discussion
In this study, we set out to determine if anti-2-[
18 F]FACPC PET-CT is of value in the detection of malignancy in known prostate adenocarcinoma lesions and metastatic lymph nodes. Five patients from an ongoing anti-[
18 F]FACBC PET-CT cohort for recurrent prostate adenocarcinoma agreed to also participate in the anti-2-[
18 F]FACPC PET-CT study. Thus, intra-patient comparison of the two radiotracers was possible. All suspicious lesions were confirmed with pathology. [12] . The mechanism of action of ACPC is competitive inhibition of valine synthesis by tumor cells [12] . Subsequently a carbon-11 ACPC radiotracer for human imaging was developed for the Oak Ridge National Laboratory high energy 86 in. cyclotron by Washburn [13] . In two studies using [ 11 C] ACPC in patients with known carcinomas, increased uptake of the radiotracer was observed [14, 15] .
In 2009, we reported the synthesis of an ACPC analog,
, where a fluorine atom replaces a hydrogen atom. This radiotracer in preclinical studies demonstrates similar activity to 11 C-ACPC; yet, with the advantage of the 110 min half-life of fluorine-18 [8] .
Based on in vitro and in vivo preclinical data of an enantiomerically enriched (ee=90%) stereoisomer, it was believed that anti-2-[
18 F]FACPC would be promising in the detection of prostate adenocarcinoma [9] . However, we have demonstrated that with humans in vivo, because of higher blood pool retention and greater renal excretion for anti-2-[
18 F]FACPC, pelvic malignant lesions are not as well visible compared with another amino acid analog radiotracer anti-[
18 F]FACBC which has lower blood pool and bladder activity. Activity in the lesions also fades with time, suggesting that even with bladder irrigation, imaging characteristics would not be optimal.
Research with anti-2-[
18 F]FACPC is ongoing to determine dosimetry and normal patterns of uptake and excretion, as well as possible utility in the evaluation of other malignancies.
Conclusions
Relatively high blood pool activity on early imaging (5 min) and bladder activity on delayed imaging (20 min) obscure evaluation of pelvic disease with the synthetic amino acid radiotracer anti-2-[
18 F]FACPC compared to better lesion conspicuity with the synthetic L-Leucine analog, anti-[ 18 F] FACBC. Though this study involved only five patients, we believe the data establish that imaging characteristics for anti-2-[
18 F]FACPC are unfavorable for pelvic prostate carcinoma detection. 
